Amit Bar-Or, MD, FRCP, FAAN, FANA

Medical School

MD - McGill University, Montreal, Québec

Internship

Medicine - Massachusetts General Hospital (MGH), Harvard Medical School (HMS), Boston, MA

Fellowship

Neurology - Massachusetts General Hospital (MGH), Harvard Medical School (HMS), Boston, MA

Postdoctoral Research Fellow, Clinical Investigator Training Program - Harvard Medical School (HMS), Massachusetts Institute of Technology, Boston, MA

Neurology - Brigham and Women's Hospital, Boston, MA

Postdoctoral Research Fellow - Cellular and Molecular Immunology, Center for Neurologic Disease, Harvard Medical School, Boston, MA

Additional Training

Certificate Program in Clinical Effectiveness - Harvard School of Public Health, Cambridge, MA

Graduate Degree

MSc in Medical Science and Translational Research - HMS and Massachusetts Institute of Technology, Cambridge, MA

Papers

2018

Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, Arnold D, O'Mahony J, Banwell B; Canadian Pediatric Demyelinating Disease Network. Thecontribution of secondhand tobacco smoke exposure to pediatric multiple sclerosisrisk. Mult Scler. 2018 Jan. 1:1352458518757089.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F,Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, JulianL, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated withocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018 Mar12;4(1):2055217318760642.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar pii: S0140-6736(18)30475-6.

Bar-Or A*, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018 May 15;90(20):e1805-e1814. 

Touil H, Kobert A, Lebeurrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J, Antel JP, Itoyama Y, Nakashima I, Bar-Or A*; Canadian B Cell Team in MS. Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis. J Neuroinflammation. 2018 Apr 19;15(1):114.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S; Canadian Pediatric Demyelinating Disease Network. Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi contrast MRI. Mult Scler. 2018 May 1:1352458518779952.

Magalhaes S, Banwell B, Bar-Or A, Fortier I, Hanwell HE, Lim M, Matt GE, Neuteboom RF, O'Riordan DL, Schneider PK, Pugliatti M, Shatenstein B, Tansey CM, Wassmer E, Wolfson C. A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit. Mult Scler. 2018 Jun 1:1352458518783345.

Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A*. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. Front Immunol. 2018 May 7;9:834:11

Galicia G, Lee DSW, Ramaglia V, Ward LA, Yam JY, Leung LYT, Li R, Handy M, Zhang J, Drohomyrecky PC, Lancaster E, Bar-Or A, Martin A, Gommerman JL. Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicda-/- and Ung-/- Mice. J Immunol. 2018 Jul 6.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health. 2018 Mar;2(3):191-204.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler. 2018 Jul 25:1352458518789884.

O'Mahony J, Marrie RA, Laporte A, Bar-Or A, Yeh EA, Brown A, Dilenge ME, Banwell B; Canadian Pediatric Demyelinating Disease Network. Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning. Mult Scler. 2018 Aug 30:1352458518796676.

Juźwik CA, Drake S, Lécuyer MA, Johnson RM, Morquette B, Zhang Y, Charabati M, Sagan SM, Bar-Or A, Prat A, Fournier AE. Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis. Sci Rep. 2018 Sep 7;8(1):13437.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIG MS Study Group. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med. 2018 Sep 13;379(11):1017-1027.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA. Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes. Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. 

2017

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A*.  Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.              J Immunol. 2017 Jan 15;198(2):691-698

Das S, Glatard T, Rogers C, Saigle J, Paiva S, MacIntyre L, Safi-Harab M, Rousseau ME, Stirling J, Khalili-Mahani N, MacFarlane D, Kostopoulos P, Rioux P, Madjar C, Lecours-Boucher X, Vanamala S, Adalat R, Mohaddes Z, Fonov VS, Milot S, Leppert I, Degroot C, Durcan TM, Campbell T, Moreau J, Dagher A, Collins DL, Karamchandani J, Bar-Or A, Fon EA, Hoge R, Baillet S, Rouleau G, Evans AC. Cyberinfrastructure for Open Science at the Montreal Neurological Institute. Front Neuroinform. 2017 Jan 6;10:53.

Montalbán X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS ;ORATORIO Clinical Investigators.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.  N Engl J Med. 2017 Jan 19;376(3):209-220 

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalbán X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.  N Engl J Med. 2017 Jan 19;376(3):221-234

Longoni G, Brown RA, MomayyezSiahkal P, Elliott C, Narayanan S, Bar-Or A, Ann Marrie R, Ann Yeh E, Filippi M, Banwell B, Arnold DL. White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. Canadian Pediatric Demyelinating Disease Network. Brain. Mar 2017

Li R, Rezk A, Li H, Gommerman JL, Prat A, Bar-Or A*; Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses. Canadian B Cells in MS Team. J Immunol. 2017 Apr 15;198(8):3245-3254

Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; Canadian Pediatric, Demyelinating Disease Network. Monophasic demyelination reduces brain growth in children. Neurology. 2017 May 2;88(18):1744-1750

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. Apr 2017

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A*. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Mult Scler. 2017.

Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, Giacomini PS, Bar-Or A, Antel J. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Mult Scler. 2017 Aug;23(9):1225-1232.

Lisak RP*, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, Touil H, Li R, Muirhead G, Bar-Or A*. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J Neuroimmunol. 2017 Aug 15;309:88-99.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Mult Scler. 2017.

Healy LM, Jang JH, Won SY, Lin YH, Touil H, Aljarallah S, Bar-Or A, Antel JP. MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Oct 16;4(6):e402.

2016

Rao VT, Ludwin SK, Fuh SC, Sawaya R, Moore CS, Ho MK, Bedell BJ, Sarnat HB, Bar-Or A, Antel JP. MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age.                J Neuropathol Exp Neurol. 2016 Feb;75(2):156-66.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.  Lancet Neurol. 2016 Apr;15(4):373-81

Healy LM, Perron G, Won SY, Michell-Robinson MA, Rezk A, Ludwin SK, Moore CS, Hall JA, Bar-Or A, Antel JP. MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells. J Immunol. 2016 Apr 15;196(8):3375-84

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.  Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.  JCI Insight. 2016;1(2)

Healy LM, Perron G, Won SY, Rao VT, Guiot MC, Moore C, Bar-Or A, Antel JP.  Differential transcriptional response profiles in human myeloid cell populations.  Clin Immunol. 2016 Apr 16. pii: S1521-6616(16)30065-1 

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M,  Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ. Long-term effects of delayed release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017 Feb;23(2):253-265

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016 Aug 6; 388(10044):576-85

Bühler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C, Gollan R, Wolf C, Lutz J, Bar-Or A, Siffrin V, Zipp F. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment. Mult Scler. 2017 Apr;23(4):567-576

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A*. Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses through a Prostaglandin E2 and myeloid-dependent mechanism. Stem Cells Transl Med. 2016 Nov;5(11):1506-1514

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.  Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148-59

Kaushik DK, Yong HYF, Hahn JN, Silva C, Jacque FH, Lisak R, Khan O, Ionette C, Larochelle C, Prat A, Bar-Or A, Yong VW.  Evaluating EMMPRIN as a marker of disease activity in multiple sclerosis: studies of serum and cerebrospinal fluid. PLoS One, 2016 Oct 11;11(10):e0163802

2015

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalbán X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC. Lipid-specific IgM bands in CSF associated with a reduced risk of developing PML during treatment with natalizumab. Ann Neurol. 77(3):447-57; 2015

Moore CS, Cui QL, Warsi NM, Durafourt BA,  Zorko N,  Owen DR,  Antel JP, and Bar-Or A*.  Direct and Indirect Effects of Immune and Central Nervous System–Resident Cells on Human Oligodendrocyte Progenitor Cell Differentiation.  J Immunol;194(2):761-72; 2015 Jan

Bar-Or A*, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F. Randomized study of teriflunomide effects on immune responses to neo-antigen and recall antigens. Neurol Neuroimmunol Neuroinflamm.;2(2):e70; 2015 Feb

Stork L, Brück W, Bar-Or A, Metz I. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol. 129(3):467-8; 2015 Jan.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology.;84(11):1145-52; 2015

Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2(2):103-18; 2015 Feb

Bin Dhuban K, d'Hennezel E, Nashi E, Bar-Or A, Rieder S, Shevach EM, Nagata S, Piccirillo CA. Coexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells.  J Immunol. 194(8):3687-96; 2015 Apr

Moore CS, Ase AR, Kinsara A, Rao VT, Michell-Robinson M, Leong SY, Butovsky O, Ludwin SK, Séguéla P, Bar-Or A, Antel JP. P2Y12 expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm.;2(2):e80; 2015 Mar

Mery V, Kimoff RJ, Suarez I, Benedetti A, Kaminska M, Robinson A, Lapierre Y, Bar-Or A, Trojan DA. High false-positive rate of questionnaire-based restless legs syndrome diagnosis in multiple sclerosis. Sleep Med.;16(7):877-82; 2015 Jul

Nyirenda MH, Morandi E, Vinkemeier U, Constantin-Teodosiu D, Drinkwater S, Mee M, King L, Podda G, Zhang GX, Ghaemmaghami A, Constantinescu CS, Bar-Or A*, Gran B*. TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. J Immunol. 94(12):5761-74; 2015 Jun

O'Mahony J, Marrie RA, Laporte A, Yeh EA, Bar-Or A, Phan C, Buckley D, Callen D, Connolly MB, Pohl D, Dilenge ME, Bernard G, Lortie A, Lowry N, MacDonald EA, Meek D, Sébire G, Venkateswaran S, Wood E, Yager J, Banwell B. Recovery From Central Nervous System Acute Demyelination in Children. Pediatrics. 136(1):e115-23; 2015 Jul

Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network. Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination. Mult Scler.2016 Mar;22(3):385-8

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore C, Michel L, Althekair F, Rajasekharan S, Gommerman J, Prat A, Fillatreau S and Bar-Or A* on behalf of the 'Canadian B cells in MS Team'. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015 Oct 21;7(310):310ra166

Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser MT, Kurukulasuriya N, Viglietta V, Fox RJ. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurol Ther. 2015 Dec;4(2):93-104

Pikor NB, Astarita JL, Summers-Deluca L, Galicia G, Qu J, Ward LA, Armstrong S, Dominguez CX, Malhotra D, Heiden B, Kay R, Castanov V, Touil H, Boon L, O'Connor P, Bar-Or A, Prat A, Ramaglia V, Ludwin S, Turley SJ, Gommerman JL. Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. Immunity. 2015 Dec 15;43(6):1160-73

Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G, Tacke R, Basat AB, Mikulski Z, Togher S, Miller J, Blatchley A, Salek-Ardakani S, Darvas M, Kaikkonen MU, Thomas GD, Lai-Wing-Sun S, Rezk A, Bar-Or A, Glass CK, Bandukwala H, Hedrick CC. Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nat Immunol. 2015 Dec;16(12):1228-34

Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle AM, Giacomini PS, Bar-Or A, Antel JP. Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann Clin Transl Neurol.  2015 Dec 2;3(1):27-41

2014

Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: The DEFINE study.  Mult Scler.  ; 20(2):243-52; 2014.

Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, Kuroda H, Fujihara K, Aoki M. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.  J Neuroimmunol. ; 268(1-2):95-8; 2014.

Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, Baranzini S, Lapierre Y, Haegert DG. Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology; 82(8):681-90; 2014.

Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A* and the Maraviroc in Multiple Sclerosis-Associated PML–IRIS (MIMSAPI) Group. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 370(5):486-8; 2014.

Shen P, T. Roch, V. Lampropoulou, R.A. O’Connor, U. Stervbo, E. Hilgenberg, S. Ries, V.D. Dang, Y. Jaimes, C. Daridon, R. Li, L. Jouneau, P. Boudinot, S. Wilantri, I. Sakwa, Y. Miyazaki, M.D. Leech, R.C. McPherson, S. Wirtz, M. Neurath, K. Hoehlig, E. Meinl, A. Grützkau, J.R. Grün, K. Horn, A.A. Kühl, T. Dörner, A. Bar-Or, S.H.E. Kaufmann, S.M. Anderton, and S. Fillatreau. IL-35-producing B cells: critical regulators of immunity during autoimmune and infectious diseases. Nature; 507(7492):366-70; 2014

Amrom D, Kinay D, Hart Y, Berkovic SF, Laxer K, Andermann F, Andermann E, Bar-Or A*. Rasmussen's encephalitis and co-morbid autoimmune diseases: a window into disease mechanism? Neurology; 16;83(12):1049-55; 2014.

Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O’Mahony J, Magalhaes S, McGowan M, Johnson T, Rajasekharan S, Narayanan S, Arnold DL, Weiner HL, Banwell B and Bar-Or A*, On behalf of the Canadian Pediatric Demyelinating Disease Network*. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis, Neurology 83(24):2219-26; 2014

Villar LM; Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, de Andrés C, Izquierdo G, Arroyo R, Avlar T, Lapin SV, Johnson T, Montalbán X, Fernández O, Álvarez-Lafuente R, Masterman D, García-Sánchez MI, Coret F, Siva A, Evdoshenko E, Álvarez-Cermeño JC, Bar-Or A*. IgM oligoclonal bands: biomarker of targetable inflammation in PPMS. Ann Neurol; 76(2):231-40; 2014

Miyazaki Y, Li R, Rezk A, Misirliyan H, Moore C, Farooqi N, Solis M, Goiry LG, de Faria Junior O, Dang VD, Colman D, Dhaunchak AS, Antel J, Gommerman J, Prat A, Fillatreau S, Bar-Or A*; CIHR/MSSC New Emerging Team Grant in Clinical Autoimmunity and the MSSRF Canadian B cells in MS Team.  A Novel MicroRNA-132-Surtuin-1 Axis Underlies Aberrant B-cell Cytokine Regulation in Patients with Relapsing-Remitting Multiple Sclerosis. PLoS One. 19;9(8):e105421; 2014

Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 261(9):1794-802; 2014

Ahn JJ, O'Mahony J, Moshkova M, Hanwell HE, Singh H, Zhang MA, Marrie RA, Bar-Or A,   Sadovnick DA, Dunn SE, Banwell BL.  Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice. Mult Scler. 21(6):735-48; 2014

Posevitz-Fejfár A, Posevitz V, Gross CC, Bhatia U, Kurth F, Schütte V, Bar-Or A, Meuth SG, Wiendl H. Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.  PLoS One.;9(12):e115920; 2014

2013

Darlington PJ, Touil T, Doucet J-S, Gaucher D, Zeidan Z, Gauchat D, Corsini R, Kim HJ, Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel JP, Prat A, Freedman MS, Atkins H, Sekaly R, Cheynier R and Bar-Or A, for the Canadian MS/BMT Study Group. Diminished Th17 (not Th1) responses underlie MS disease abrogation after HSCT. Ann Neurol; 73(3):341-54. Mar 2013

Koeva V, Bar-Or A, Gendron D, Backman SB. Epidural blood patch in a patient with multiple sclerosis: is it safe? Can J Anaesth. 60(5):479-483. May 2013

Van Haren K, Tomooka BH, Kidd BA, Banwell B, Bar-Or A, Chitnis T, Tenembaum SN, Pohl D, Rostasy K, Dale RC, O'Connor KC, Hafler DA, Steinman L, Robinson WH. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing- remitting multiple sclerosis. Mult Scler. Apr 23 2013

Wu C, Leong SY, Moore CS, Cui QL, Gris P, Bernier LP, Johnson TA, Séguéla P, Kennedy TE, Bar-Or A, Antel JP. Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J Neuroinflammation. 10:41, Mar 19 2013

Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson KT. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. June 2013

Moore CS, Rao V, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A, Antel JP. Mir-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol.  2013

Verhey LH, Signori A, Arnold DL, Bar-Or A, Sadovnick AD, Marrie RA, Banwell B, Sormani MP. Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology. Aug 21 2013.

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 81(6):552-8. Aug 6 2013

Henault D, Galleguillos L, Moore C, Johnson T, Bar-Or A, Antel J. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.  Neurology.  ; 81(20):1768-72.  Nov 12, 2013

Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, Skoromets A, Bar-Or* A. Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. ISRN Neurol. 748127.  Sep 10, 2013

Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostásy K, Berger T, Dale RC, Brilot F, Olsson T, Jenne D, Pröbstel AK, Dornmair K, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A*, Meinl E*. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol. 191(7):3594-604. Oct  2013

Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A*, Banwell B*; Canadian Pediatric Demyelinating Disease Network. Epstein-Barr virus in oral shedding of children with multiple sclerosis. Neurology. ;81(16):1392-9; 2013.

van Pelt ED, Mescheriakova JY, Makhani N, Ketelslegers IA, Neuteboom RF, Kundu S, Broer L, Janssens C, Catsman-Berrevoets CE, van Duijn CM, Banwell B, Bar-Or A*, Hintzen RQ*. Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology. ;81(23):1996-2001; 2013.

2012

Trojan DA, Kaminska M, Bar-Or A, Benedetti A, Lapierre Y, Da Costa D, Robinson A, Cardoso M, Schwartzman K, Kimoff RJ. Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis. J Neurol Sci. 316(1-2):158-63, 2012

Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, Bar-Or A, Antel JP. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia, 60(5):717-27, 2012

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology, 78(9):665-71, 2012

Pool M, Rambaldi I, Darlington PJ, Wright MC, Fournier AE*, Bar-Or* A. Neurite outgrowth is differentially impacted by distinct immune cell subsets. Mol Cell Neurosci. 49(1):68-76, 2012

Vazquez-Tello A, Halwani R, Li R, Nadigel J, Bar-Or A, Mazer BD, Eidelman DH, Al-Muhsen S, Hamid Q. IL-17A and IL-17F Expression in B Lymphocytes. Int Arch Allergy Immunol, 157(4):406-416, 2012

Dhaunchak AS, Becker C, Schulman H, De Faria O Jr, Rajasekharan S, Banwell B, Colman DR, Bar-Or A*; on behalf of the Canadian Pediatric Demyelinating Disease Group. Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol. May;71(5):601-613; 2012

Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman L, O'Connor P. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler, 2012

Kaminska M, Kimoff R, Benedetti A, Robinson A, Bar-Or A, Lapierre Y, Schwartzman K, Trojan D. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler, 2012.

de Faria O Jr, Cui QL, Bin JM, Bull SJ, Kennedy TE, Bar-Or A, Antel JP, Colman DR, Dhaunchak AS. Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes. Front Genet.;3:46. Epub 2012 Mar 28, 2012

aubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; On behalf of the ITN STAyCIS Study Group; Work on this study was conducted on the behalf of the ITN STAyCIS Study Group; ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study. Neurology. 2012 Apr 10;78(15):1171-1178. May 2012

Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A*. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol.;246(1-2):85-95. Mar 28 2012

Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, Fillatreau S, Gray D. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. Apr 30, 2012

Belabani C, Rajasekharan S, Johnson T and Bar-Or A* on behalf of the CIHR/MSSC NET in Clinical Autoimmunity and the Canadian Pediatric Demyelinating Disease Network. A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples.  J Immunol Meth; 387 (1-2):1-10. Jan 31 2013

Côté I, Trojan DA, Kaminska M, Cardoso M, Benedetti A, Weiss D, Robinson A, Bar-Or A, Lapierre Y, Kimoff RJ. Impact of Sleep Disorder Treatment on Fatigue in Multiple Sclerosis. Mult Scler, 2012

O'Mahony J, Bar-Or A, Arnold DL, Sadovnick AD, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network. Masquerades of Acquired Demyelination in Children: Experiences of a National Demyelinating Disease Program. J Child Neurol. 2012

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med; 367(12):1098-107. Sep 20 2012

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med;367(12):1087-97. Sep 2012

Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, Sled JG, Bar-Or A, Sadovnick AD, McGowan M, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol. Aug; 72(2):211-23. 2012

2011

Durafourt BA#, Lambert C#, Johnson TA, Blain M, Bar-Or A, Antel JP.  Differential Responses of Human Microglia and Blood Derived Myeloid Cells to FTY720. J Neuroimmunol, 230(1-2):10-6, (#equal contribution), Jan 2011

Comi G, Cohen JA, Arnold DL, Wynn D, and the FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol, 69(1):75-82, Jan 2011

De Vidi I, Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, Mettling C, Lin YL, Thouvenot E, Carlander B, Camu W, Antel JP, Bar-Or A, Zephir H, Vermersch P, De Seze J, Corbeau P, Eliaou JF, Vincent T. Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol, 138(3):239-46, Mar 2011

Venkateswaran S, Zheng K, Sacchetti M, Gagne D, Arnold DL, Sadovnick D, Scherer SW, Banwell B, Bar-Or A*, Simon DK*, on behalf of the Canadian Pediatric Demyelinating Disease Network. Mitochondrial DNA Haplogroups and Mutations in Pediatric Acquired Central Demyelination. Neurology, 1;76(9):774-80, 2011

Disanto G#  Magalhaes M#, Handel A,  Morrison KM,  Sadovnick AD,   Ebers GC, Banwell B, Bar-Or A*, on behalf of the Canadian Pediatric Demyelinating Disease Network. HLA-DRB1 Confers Increased Risk of Pediatric-Onset MS in Children with Acquired Demyelination. Neurology, 76(9):781-6,   (# equal contribution), 2011

Haegert DG, Hackenbroch JD, Duszczyszyn D, Fitz-Gerald L, Zastepa E, Mason H, Lapierre Y, Antel J, Bar-Or A. Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS). J Neuroimmunol, 233(1-2):233-9, 2011

Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O'Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand'Maison F, Baird JB, Bhan V, Marrie RA. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neuro, 10(5):436-45, May 2011

Johnson TA, Evans BL, Durafourt BA, Blain M, Lapierre Y, Bar-Or A, Antel JP. Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients.   J Immunol, 1;187(1):570-9, July 2011

Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci, 18(7):997-8, July 2011

Pool M, Rambaldi I, Durafourt BA, Wright MC, Antel JP, Bar-Or A*, Fournier AE*. Myeloid lineage cells inhibit neurite outgrowth through a myosin II-dependent mechanism. J Neuroimmunol, 15;237(1-2):101-5, 2011

Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, O'Connor P, D'Souza C, Ursell M, Burton JM.  Cholecalciferol Plus Calcium Suppresses Abnormal PBMC Reactivity in Patients with Multiple Sclerosis. J Clin Endocrinol Metab,;96(9):2826-34, 2011

Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B. TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function. J Immunol, 187(5):2278-90, 2011

Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U, Krumbholz M, Kuempfel T, Blaschek A, Stark W, Gärtner J, Pohl D, Rostasy K, Weber F, Forne I, Khademi M, Olsson T, Brilot F, Tantsis E, Dale RC, Wekerle H, Hohlfeld R, Banwell B*, Bar-Or A*, Meinl E*, Derfuss T*. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology, 9;77(6):580-8, 2011

Darlington P, Touil T, Doucet J-S, Gaucher D, Zeidan J, Gauchat D, Corsini R, Kim HJ, Duddy M,   Jalili F, Kebir H, Arbour N, Chen J, Arnold DL, Bowman M, Antel JP, Prat A, Freedman MS, Atkins H, Sekaly R, Cheynier R and Bar-Or A* for the Canadian MS/BMT Study Group. Diminished Th17 (not Th1) responses underlie MS disease abrogation after BMT. Accepted, Ann Neurol, 2011

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; On behalf of the MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology, 77(16):1551-60. 2011

Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multicentre trial. Lancet, 19;378(9805):1779-87, Nov 2011

Verhey LH, Branson HM, Shroff MM, Callen DJ, Sled JG, Narayanan S, Sadovnick AD, Bar-Or A, Arnold DL, Marrie RA, Banwell B; for the Canadian Pediatric Demyelinating Disease Network. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol, 10(12):1065-1073, Dec 2011

2010

Comi G, O'Connor P, Montalbán X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group. Phase II study of oral Fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler, 16(2):197-207, 2010

Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell  M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology, 75(11), 2010

O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J, Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA, Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M, Hancock MA, Gano D, Fattahie R,  Kopel L, Fournier AE, Moscarello M, Banwell B and Bar-Or A. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol, 223(1-2):92-9, 2010

Johnson TA, Shames I, Keezer M, Lapierre Y, Haegert DG, Bar-Or A, Antel J. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol, 137(1):15-20, 2010

Bar-Or A*, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith C. Abnormal B cell cytokine responses: A trigger of T-cell-mediated disease in MS? Ann Neurol, 67(4):452-61, 2010

Zhang Y, Jalili F, Ouamara N, Zameer A, Cosentino G, Mayne M, Hayardeny L, Antel JP,  Bar-Or A*, John GR*. Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: Role of IGF-2. J Neuroimmunol, 227(1-2):71-9, 2010

Newell MK, Tobin RP, Cabrera JH, Sorensen MB, Huckstep A, Villalobos-Menuey EM,  Burnett M, McCrea E, Harvey CP, Buddiga A, Bar-Or A, Freedman MS, Nalbantoglu J, Arbour N, Zamvil SS, Antel JP. TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leukoc Biol, 88(4):779-89, 2010

Dhaunchak AS, Huang J, De Faria Junior O, Roth A, Pedraza L, Antel JP, Bar-Or A, Colman D. A proteome map of axoglial specializations isolated and purified from human central nervous system.  Glia, 58(16):1949-60, 2010

Johnson TA, Lapierre Y, Bar-Or A, Antel JP. Distinct properties of circulating CD8+ T cells in FTY720 treated multiple sclerosis patients. Arch Neurol, 67(12):1449-55, 2010

Darlington P, Boivin M-N, Renoux C, Francois M, Atkins HL, Freedman MS, Galipeau J, Cohen JA, Solchaga L, Bar-Or A*. Th1 and Th17 Regulation by Mesenchymal Stem Cells: Implication for MS. Ann Neurol, 68(4):540-5, 2010

2009

O'Connor P, Comi G, Montalbán X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L. FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology, 6;72(1):73-9, 6 Jan 2009

Banwell B*, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, Connolly MB, Yager J, Mah JK, Shah N, Sebire G, Meaney B, Dilenge ME, Lortie A, Whiting S, Doja A, Levin S, MacDonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Guimond C, Cooper P, Grand’Maison F, Baird JB, Bhan V, Bar-Or A*. Incidence of acquired demyelination of the CNS in Canadian children. Neurology, 72(3) :232-9, 20 Jan 2009

Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T, Bar-Or A, Tong C,  Hauser SL, Oksenberg JR. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch Neurol, 66(2):226-33, Feb 2009

Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW, GLANCE Investigators. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology, 72(9):806-12, 3 March 2009

Trojan DA, Arnold DL, Shapiro S, Bar-Or A, Robinson A, Le Cruguel JP, Narayanan S,  Tartaglia MC, Caramanos Z, Da Costa D. Fatigue in post-poliomyelitis syndrome: association with disease-related, behavioral, and psychosocial factors. PMR, 1(5):442-9, May 2009

Pool M, Niino M, Rambaldi I, Robson K, Bar-Or A*, Fournier AE*. Myelin regulates immune cell adhesion and motility. Exp Neurol, 217(2):371-7, June 2009

Bar-Or A*, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler, 15(8):959-64, Aug 2009

McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, Kuhle J, Kappos L, Rostasy K, Pohl D, Gagne D, Ness JM, Tenembaum S, O'Connor KC, Viglietta V, Wong SJ, Tavakoli NP, de Seze J, Idrissova Z, Khoury SJ, Bar-Or A, Hafler DA, Banwell B, Wucherpfennig KW. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol, 183(6):4067-76, 15. Sep 2009

2008

Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, Bar-Or A, Weinshenker BG, Lucchinetti CF, Pittock SJ. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology, 70(5):344-52, 2008

Pool M, Thiemann J, Bar-Or A, Fournier A. NeuriteTracer: A novel Image plugin for automated quantification of neurite outgrowth. J Neurosci Meth, 168(1):134-9, 2008

Banwell B, Bar-Or A*, Cheung R3, Kennedy J1, Becker DJ, Dosch HM*, on behalf of the Wadsworth Pediatric Multiple Sclerosis Study. Abnormal T cell reactivities to target-organ and environmental antigens in childhood multiple sclerosis and diabetes implicate both shared and distinct autoimmune disease mechanisms. Ann Neurol, 63(1):98-111, 2008

Hauser S, Waubant E, Arnold D, Vollmer T, Antel JP, Fox R, Bar-Or A, Sarkar N, Langer-Gould A, Panzara M, Smith C. B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis. NEJM, 14; 358(7):676-88, 2008

Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL; the Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol, 63(2):254-62, 2008

Ghassemi R, Antel SB, Narayanan S, Francis SJ, Bar-Or A, Sadovnick AD, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Study Group. Lesion distribution in children with clinically isolated syndromes. Ann Neurol, 63(3):401-5, March 2008

Schrijver HM, De Palma R, Sementa A, Chaudhuri A, Behan PO, Hauser SL, Waubant E, Bar-Or A; the HERMES Trial Group. Rituximab in Relapsing-Remitting Multiple Sclerosis. N Engl J Med, 12;358(24):2645-2647, 2008

Bar-Or A*, Calabresi P, Arnold D.L., Markowitz C, Shafer S, Kasper L, Waubant E, Gazda S, Fox R, Panzara M, Sarkar N, Agarwal S, Smith C. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol, 63(3):395-400, 2008

Darlington PJ, Podjaski C, Horn KE, Costantino S, Blain M, Saikali P, Chen Z, Freedman M, Wiseman PW, Bar-Or A, Kennedy TE, Antel JP  Innate immune-mediated Neuronal Injury Consequent to Loss of Astrocytes. JNEN, 67(6):590-9, 2008

Fordyce CB, Gagne D, Jalili F, Alatab S, Arnold DL, Da Costa D, Sawoszczuk S, Bodner C, Shapiro S, Collet J-P, Robinson A, Le Cruguel J-P, Lapierre Y, Bar-Or A*, Trojan DA*. Elevated Serum Inflammatory Markers in Post-Poliomyelitis Syndrome. J Neurol, 15;271(1-2):80-6, 2008

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler, 14(5):663-70, 2008

Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel JP. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008;181(8):5730-7

Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology, 71(16):1261-7, 2008

Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol, 255(10):1473-8, 2008

Lambert C, Desbarats J, Arbour N, Hall JA, Olivier A, Bar-Or A, Antel JP. Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia. J Immunol, 181(12):8288-97, 2008

2007

O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Robinson WH, Cherry SV, Bar-Or A, Banwell B, Fukaura H, Tenembaum S, Wong SL, Rostasy K, Dale R, Freedman M, Steinman L, Hafler DA, Wucherpfennig KW. Self-Antigen Tetramers Discriminate between Myelin Autoantibodies to Native or Denatured Protein. Nat Med, 13(2):211-7, 2007

Nuttall RK, Silva K, Hader W, Bar-Or A, Patel K, Edwards DR, Yong VW. Metalloproteinases (MMPs and ADAMs) are enriched in microglia compared to leukocytes and they regulate cytokine levels in activated Microglia. Glia, 1; 55(5):516-26, 2007

Antel J, Bar-Or A, Gold R, Tabira T. 8th international congress of neuroimmunology.  J Neuroimmunology, 185(1-2):6-8, 2007

Trojan D, Arnold D, Collet J-P, Shapiro S, Bar-Or A, Bernasconi A, Robinson A, Le Cruguel J-P, Ducruet T, Narayanan S, Arcelin K, Wong AM, Tartaglia MC, Lapierre Y, Caramanos Z, Da Costa D. Fatigue in Multiple sclerosis: Association with disease related, behavioral and psychosocial factors. Mult Scler, 13 (8):985-95, 2007

Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A*. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol, 15;178(10):6092-9, 2007

Banwell B*, Krupp L, Tellier R, Kennedy J, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah J, Stoian C, Kremenchutzky M, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh A, Farrell K, Freedman M, Iivanainen M, Stephens D and Bar-Or A*. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol, 6(9):773-81, 2007

Bar-Or A*, Vollmer T*, Antel JP, Arnold D, Bodner C, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FY, Utz PJ, Valone F, Weiner L, Steinman L and Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase I/II trial. Arch Neurol, 64(10):1407-15, 2007

2006

Duszczyszyn DA, Beck JD, Antel JP, Bar-Or A, Lapierre Y, Gadag V, Haegert DG.  Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clin Exp Immunol,  143 (2), 305-13, 2006

O’Connor P, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart J, Scheyer R, on behalf of the Teriflunomide Multiple Sclerosis Trial Group and the University of BC MS/MRI Research group. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology,  66; 894-900, 2006

Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand’Maison F, Bar-Or A*.  Natalizumab effects on Immune Responses in multiple sclerosis. Ann Neurol, 59(5):748-54, 2006

Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. Altered CD4:CD8 T cells Ratios in Cerebrospinal spinal Fluid of Natalizumab-treated Patients with Multiple Sclerosis. Arch Neurol, 63(10):1383-7, Oct 2006

Kilpatrick LM, Harris RL, Owen KA, Bass R, Ghorayeb C, Bar-Or A*, Ellis V*. Initiation of plasminogen activation on the surface of monocytes expressing the type-II transmembrane serine protease matriptase. Blood, 15;108(8):2616-23, 2006

Bar-Or A* and Antel JP. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol, 180(1-2):3-8, Nov 2006

Shapiro AM, Jack CS, Lapierre Y, Arbour N, Bar-Or A, Antel JP. Potential for interferon Beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system. Arch Neurol, 63(9):1296-9, Sept 2006

Chen JT, Collins DL, Atkins HL, Freedman MS, Galal A, Arnold DL. Canadian MS BMT Study Group. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology, 66(12):1935-7, 2006

Antony JM, Izad M, Bar-Or A, Warren K, Vodjgani M, Mallet F and Power C. Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. In process, AIDS Res Hum Retrovirus, 22(12):1253-9, 2006

2005

Guiliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J Neuroimmunol, 158(1-2):213-21, 2005

Magnus T, Schreiner B, Korn T, Jack C, Antel JP, Ifergan I, Chen L, Bar-Or A*, Wiendl H*.  Microglial expression of the B7-family member B7homolog 1 confers strong immune inhibition: implications for immune response and autoimmunity in the CNS. J Neurosci, 25(10):2537-2546, 2005

Poppe A, Wardell L, Lowden D, Lapierre Y, Bar-Or A*. Hypothalamic involvement in Devic’s Neuromyelitis Optica. Multiple Sclerosis, 11(5); 617-621, 2005

Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J Neurosci, 81(3):363-73, 2005

Arbour A, Rastikerdar E, McCrea E, Lapierre Y, Dörr J, Bar-Or A, Antel JP. Upregulation of TRAIL expression on human T lymphocytes by Interferon  and Glatiramer acetate. Multiple Sclerosis, 11(6):652-7, 2005

Chen JT, Collins DL, Freedman MS, Atkins H, Arnold DL, The Canadian MS/BMT Study Group. Local MTR signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage, 25(4):1272-8, 2005

Wiendl H, Feger U, Mittelbronn M, Schreiner B, Stadelmann C, Antel JP, Brueck W,    Meyermann R, Bar-Or A, Kieseier BC, Weller M.  Expression of the non-classical major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 128(Pt 11):2689-704, 2005

2004

Duddy ME, Alter A, Bar-Or A*. Distinct profiles of human B cell effectors cytokines: A role in immune regulation? J Immunol, 172(6):3422-7, 2004

Kim HJ, Biernacki K, Prat A, Antel JP, Bar-Or A*. Effects of glatiramer acetate-reactive T cells from patients with multiple sclerosis on human Brain Endothelial Cells: Efficient migration without enhanced inflammation. Clin Immunol, 111:35-46, 2004

Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A*. Type-2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.                    J Immunol, 172: 7144-7153, 2004

Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-Effectiveness of IFNβ 1a, IFNβ 1b, and Glatiramer Acetate in Non-Primary Progressive Multiple Sclerosis. Value in Health, 7(5):554-568, 2004

Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol, 251 (Suppl 5), V12-29, 2004

2003

Oliveira EML*, Bar-Or A*, Waliszewska AI, Cai G, Anderson DE, Krieger JI, Hafler DA. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. J Autoimmunity, 20:71-81, 2003

Seguin R, Biernacki K, Prat A,Wosik K, Kim H-J, Blain M, McCrea E, Bar-Or A, Antel JP. Differential effects of Th1/Th2 lymphocyte supernatants on human microglia. Glia, 42(1):36-45, 2003

O'Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S, Wucherpfennig KW, Hafler DA. Myelin basic protein-reactive autoantibodies in the serum and CSF of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol, 136(1-2):140-148, 2003

Alter A, Duddy M, Hebert S, Biernacki K, Prat A, Antel JP, Yong VW, Nuttall RK, Pennington CJ, Edwards DR, Bar-Or A*. Determinants of human B cell migration across brain endothelial cells.  J Immunol, 170(9):4497-4505, 2003

Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis.  Multiple Sclerosis, 9:311-319, 2003

Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL. Increased T cell reactivity to amyloid-beta protein in older humans and patients with Alzheimer disease. J Clin Invest, 112(3):415-422, 2003

Antel JP and Bar-Or A. Do myelin antibodies predict the diagnosis of multiple sclerosis? NEJM, 349(2):107-109, 2003

Bar-Or A*, Nuttall RK*, Duddy M, Alter A, Kim HJ, Ifergan I, Pennington CJ, Bourgoin P, Edwards DR,Yong VW. Analyses of all matrix metalloproteinase members in leukocytes: monocytes as major inflammatory mediators in Multiple Sclerosis. Brain, 126: 2738-2749, 2003

2002

Kim HJ, Antel JP, Duquette P, Alleva D, Conlon PJ, Bar-Or A*. Persistence of immune responses to altered and native myelin antigens in patients with Multiple Sclerosis treated with altered peptide ligand. J Immunol, 104(2):105, 2002

Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting MS.  Med Dec Making, 22:506-513, 2002

2001

Bar-Or A*, Oliveira EML, Anderson DE, Krieger JI, Duddy M, O'Connor KC, Hafler DA. Immunological Memory: Contribution of Memory B Cells Expressing Costimulatory Molecules in the Resting State. J Immunol, 167(10):5669-5677, 2001

2000

Anderson DE, Bieganowska K, Bar-Or A, Oliveira EML, Hafler DA. Paradoxical inhibition of T cell function in response to CTLA-4 blockade: heterogeneity within the human T cell repertoire. Nat Med, 6:211-214, 2000

Kipp B, Bar-Or A, Gausling G, Oliveira EM, Fruhan SA, Stuart DH, Hafler DA. A novel population of B7-1+ T cells producing intracellular IL-4 is decreased in patients with multiple sclerosis. Eur.J.Immunol, 30:2092-2100, 2000

1992

Williams K, Bar-Or A, Antel JP, Yong VW. Adult human microglia: biological characteristics compared with astrocytes & blood monocytes. J Neurop and Exp Neurol, 51(5):538-549, 1992

1991

Brown GM, Bar-Or A, Grossi D, Kashur S. Urinary 6-sulfatoxymelatonin, an index of pineal function in the rat. J Pineal Res, 10 (3):141-147, 1991

1989

Bar-Or A, Brown GM. Pineal involvement in diurnal rhythm of nociception in the rat. Life Sci, 44 (16):1067-1075, 1989

Abstracts

2018

Benjamins J, Nedelkoska L, Touil H, Stemmer P, Carruthers N, Bar-Or A, Lisak R. Proteomic Analysis of Supernatants of Cultured B Cells from Multiple Scelrosis Patients Compared to Controls. The American Society for Experimental Neurotherapeutics (ASENT) 20th Annual Meeting. Rockville, MD. Mar 2018.

Grover S, Yea C, Berenbaum T, Nandamalavan D, Iruthayanathan R, Wilbur C, Albassam F, Longoni G, Reginald A, Wan M, Costello F, O’Mahony J, Arnold D, Banwell B, Bar-Or A, Marrie R, Mabbott D, Yeh E. Retinal Nerve Fiber Layer (RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth. American Academicy of Neurology (AAN) 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Cohen J, Comi G, Selmaj K, Bar-Or A, Arnold D, Steinman L, Hartung H, Montalbán X, Havrdová E, Cree B, Sheffield J, Raghupathi K, Kappos L. Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon -1a in Relapsing Multiple Sclerosis (RMS). AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Comi G, Arnold D, Cree B, Kappos L, Selmaj K, Bar-Or A, Steinman L, Hartung H, Montalbán X, Havrdová E, Sheffield J, Raghupathi K, Cohen J. Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM). AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Patterson K, Burnor E, Bar-Or A, Lancaster E. Mechanisms of autoantibodies to neurofascins in acquired demyelinating neuropathies. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Cohen J, Bar-Or A, Cree B, Mao-Draayer Y, Han M, Singer B, Jannu A, Kolodny S, Meng X, Winger R. Investigating Immune Phenotype Biomarker Changes in Patients with Relapsing MS Treated with Fingolimod 0.5 mg/day: The FLUENT Study. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Freedman M, Bar-Or A, Benamor M, Truffinet P, Poole E, Mandel M, Kremenchutzky M. Long-term Disability Outcomes in Patients Treated With Teriflunomide for up to 14 Years: Group- and Patient-Level Data From the Phase 2 Extension Study. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Bar-Or A, Gelfand J, Fiore D, Harp C, Zheng H, Herman A, Musch B, Cross A. Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS). AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Benedict R, Cree B, Tomic D, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Karlsson G, Dahlke F, Kappos L. Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Arnold D, Kappos L, Hauser S, Montalban X, Traboulsee A, Wolinsky J, Levesque V, Villoslada p, Belachew S, Model F, Hubeaux S, Bar-Or A. Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Banwell B, Arnold D, Bar-Or A, Ghezzi A, Greenberg B, Waubant E, Giovannoni G, Wolinsky J, Gärtner J, Rostasy K, Krupp L, Tardieu M, Brück W, Stites T, Chen Y, Merschhemke M, Chitnis T. Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Cree B, Fox R, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Magnusson B, Rouyrre N, Piani Meier D, Tomic D, Karlsson G, Dahlke F, Kappos L. Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Kappos L, Selmaj K, Bar-Or A, Comi G, Arnold D, Steinman L, Hartung H, Montalbán X, Havrdová E, Sheffield J, Raghupathi K, Cree B, Cohen J. Efficacy of Ozanimod Versus Interferon-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B). AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Fadda G, Brown R, Longoni G, Castro D, O’Mahony J, Verhey L, Branson H, Bar-Or A, Marrie R, Yeh E, Narayanan S, Arnold D, Banwell B. MRI Contributions to the Diagnosis of Multiple Sclerosis in Children. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Cree B, Bar-Or A, Comi G, Selmaj K, Arnold D, Steinman L, Hartung H, Montalbán X, Havrdová E, Sheffield J, Raghupathi K, Kappos L, Cohen J. Safety of Ozanimod Versus Interferon -1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B). AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Stokmaier D, Winthrop K, Chognot C, Evershed J, Manfrini M, McNamara J, Bar-Or A. Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis. AAN 70th Annual Meeting. Los Angeles, CA. Apr 2018.

Giovannoni G, Hartung H.-P, Arnold D, Bar-Or A, Comi G, de Seze J, Hauser S, Hemmer B, Kappos L, Lublin F, Montalbán X, Rammohan K, Selmaj K, Traboulsee A, Chin P, Li C, Mairon N, Napieralski J, Wolinsky J. Infections in Ocrelizumab Recipients From Phase III Studies. Association of British Neurologists (ABN) Annual Meeting. Birmingham, UK. May 2018.

Arnold D, Kappos L, Hauser S, Montalbán X, Traboulsee A, Wolinsky J, Levesque V, Villoslada P, Belachew S, Model F, Hubeaux S, Bar-Or A. Brain MRI Activity and Atrophy in Ocrelizumab-Treated Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled OPERA Trials. Annual Consortiums of Multiple Sclerosis (CMSC) Meeting. Nashville, TN. May 2018.

O’Mahony J, Marrie RA, Bar-Or A, Yeh E, Banwell B. Pediatric-Onset Multiple Sclerosis is Associated with Reduced Parental Health-Related Quality of Life and Family Functioning. Annual CMSC Meeting. Nashville, TN. May 2018.

Wolinsky J, Montalbán X, Hauser S, Kappos L, Julian L, Manfrini M, Belachew S, Model F, Hubeaux S, Bar-Or A. Prespecified Subgroup Analyses of Ocrelizumab Efficacy in patients with Primary Progressive Multiple Sclerosis from the Phase III ORATORIO Study. Annual CMSC Meeting. Nashville, TN. May 2018.

Arnold D, Banwell B, Bar-Or A, Ghezzi A, Greenberg B, Waubant E, Giovannoni G, Wolinsky J, Gaertner J, Rostasy K, Krupp L, Tardieu M, Brueck W, Stites T, Pearce G, Merschhemke M, Chitnis T. Effects of Fingolimod on Magnetic Resonance Imaging Outcomes in Patients with Pediatric-Onset Multiple Sclerosis: Results from the Phase 3 Paradigms Study. Annual CMSC Meeting. Nashville, TN. May 2018.

Dunn C, Yea C, Hanwell H, Yeh E, Marrie RA, Bar-Or A, Ebrahimi N, Banwell B, O’Mahony J. Relationship Between Skin Tone and Pediatric-Onset Multiple Sclerosis (MS). Annual CMSC Meeting. Nashville, TN. May 2018.

Stokmaier D, Winthrop K, Chognot C, Evershed J, Manfrini M, McNamara J, Bar-Or A. Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis. Annual CMSC Meeting. Nashville, TN. May 2018.

Kappos L, Montalbán X, Hauser S, Julian L, Manfrini M, Belachew S, Model F, Hubeaux S, Bar-Or A, Wolinsky J. Prespecified Subgroup Analyses of Ocrelizumab Efficacy in Patients with Primary Progressive Multiple Sclerosis from the Phase III ORATORIO Study. European Academy of Neurology (EAN) 4th Congress. Lisbon, Portugal. Jun 2018.

Benedict R, Cree B, Tomic D, Fox R, Giovannoni G, Bar-Or A, Gold R, Vermersch P, Pohlmann H, Karlsson G, Dahlke F, Kappos L. Siponimod Improves Cognitive Processing Speed in Patients with SPMS: Results from Phase 3 EXPAND Study. EAN 4th Congress. Lisbon, Portugal. Jun 2018.

Cree B, Fox R, Giovannoni G, Vermersch P, Bar-Or A, Gold R, Magnusson B, Rouyrre N, Meier D, Tomic D, Karlsson G, Dahlke F, Kappos L. Siponimod Affects Disability Progression in SPMS Patients Independent of Relapse Activity: Results from the Phase III EXPAND Study. EAN 4th Congress. Lisbon, Portugal. Jun 2018.

Stokmaler D, Winthrop K, Chognot C, Evershed J, Manfrini M, McNamara J, Bar-Or A. Effect of Ocrelizumab on Vaccine Responses in Patients with Multiple Sclerosis. EAN 4th Congress. Lisbon, Portugal. Jun 2018.

Cohen J, Comi G, Bar-Or A, Selmaj K, Arnold D, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Sheffield J, Raghupathi K, Cree B, Kappos L. Efficacy of ozanimod verses interferon beta-1a by DMT treatment experience and EDSS categorization from a multicenter, randomized, double-blind phase 3 study of relapsing multiple sclerosis. EAN 4th Congress. Lisbon, Portugal. Jun 2018.

Darlington P, Stopnicki B, Touil T, Doucet J.-S, Fawaz L, Roberts M, Boivin M.-N, Arbour N, Freedman M, Atkins H, Bar-Or A. Natural Killer Cells Regulate Th17 cells After Autologous Hemtopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. 2018 Meeting of the Canadian Society for Immunology (CSI). London, Ontario. Jun 2018.

Patterson K, Burnor E, Bar-Or A, Lancaster E. Mechanisms of autoantibodies to neurofascins in demyelinating diseases. 14th International Congress of Neuroimmunology (ISNI). Brisbane, Australia. Aug 2018.

Waters P, Fadda G, Woodhall M, Irani S, Banwell B, Bar-Or A. MOG IgG1 Antibodies in Children. 14th ISNI. Brisbane, Australia. Aug 2018.

Kappos L, Arnold D, Hauser S, Montalbán X, Traboulsee A, Wolinksy J, Levesque V, Villoslada P, Belachew S, Model F, Hubeaux S, Bar-Or A. Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Paitents with Relapsing Multiple Sclerosis. Deutschen Gesellschaft für Neurologie/The German Society for Neurology (DGN) 2018. Berlin, Germany. Oct 2018.

Cohen J, Comi G, Selmaj K, Bar-Or A, Arnold D, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Cree B, Sheffield J, Raghupathi K, Kappos L. Ozanimod vs. Interferon -1a: Clinical and MRI Results of RADIANCE Part B – A 2-Year Phase 3 Trial in Relapsing Multiple Sclerosis. DGN 2018. Berlin, Germany. Oct 2018.

Kappos L, Bar-Or A, Comi G, Selmaj K, Arnold D, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Sheffield J, Raghupathi K, Cree B, Cohen J. Efficacy of O Versus Interferon -1a by Prior Treatment and Baseline Disability in Two Multicentre, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B). DGN 2018. Berlin, Germany. Oct 2018.

Comi G, Kappos L, Selmaj K, Bar-Or A, Arnold D, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Cree B, Sheffield J, Raghupathi K, Cohen J. Ozanimod Demonstrates Efficacy and Safety in a Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM). DGN 2018. Berlin, Germany. Oct 2018.

Stokmaier D, Winthrop K, Chognot C, Evershed J, Manfrini M, McNamara J, Bar-Or A. Effect of Ocrelizumab on Vaccine Responses in Patients with Multiple Sclerosis. DGN 2018. Berlin, Germany. Oct 2018.

2017

Rammohan KW, Hartung H-P, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hauser SL,  Hemmer B, Kappos L, Lublin F, Montalbán X, Selmaj K, Traboulsee A, Chin P, Li C, Mairon N, Napieralski J, Wolinsky J.  Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis.  ACTRIMS. Orlando, Florida.  Feb 2017

Traboulsee A, Giovannoni G, Bar-Or A, Comi C, Hartung H-P, Havrdová E, Kappos L, Lublin F, Selmaj K, Han J, Julian L, Belachew S, Hauser SL.  NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies.  ACTRIMS. Orlando, Florida.  Feb 2017

Wolinsky J, Montalbán X, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Hemmer B, Rammohan KW, Deol-Bhullar G, Masterman D, Wei W, Chin P, Bernasconi C, Belachew S.  Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial.  ACTRIMS. Orlando, Florida.  Feb 2017

Chitnis T, Arnold D, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostasy K, Tardieu M, Waubant E, Wolinsky J, Bar-Or A, Stites T, Jessop N, Bernhard Merschhemke M, Gärtner J. Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon ß-1a. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Brown R, O'Mahony J, Ann Yeh E, Marrie R, Bar-Or A, Banwell B, Arnold D. Evidence Supporting the Use of MRI as a Surrogate for Clinical Endpoints in Randomized Controlled Trials for Pediatric Multiple Sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Lisak R, Nedelkoska L, Touil H, Li R, Stemmer P, Bar-Or A, Benjamins. Death of oligodendrocytes induced by secretory products of B cells of patients with relapsing multiple sclerosis is mediated by extracellular vesicles. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Barkhof F, Kappos L, Bar-Or A, Li D, Belachew S, Julian L, Sauter A, Stokmaier D, Hauser S. Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing- Remitting Multiple Sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Hauser S, Bar-Or A, Cohen J, Comi G, Correale J, Coyle P, Cross A, De Seze J, Montalbán X, Selmaj K, Heinz W, Kakarieka A, Karlsson G, Häring D, Wallström E, Kappos L. Oftumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II). American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Freitas C, O'Mahony J, Zahavich L, Guimond C, Ann Yeh E, Arnold D, Bar-Or A, Sadovnick D, Marrie R, Banwell B. Adverse early life events are not associated with pediatric multiple sclerosis (MS). American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S, Sidorenko T, Wolf C, Wallström E, Dahlke F. Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Cohen J, Selmaj K, Arnold D, Comi G, Bar-Or A, Olson A, Kopicko J, Frohna P. Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Wolinsky J, Montalbán X, Kappos L, Hauser H, Giovannoni G, de Seze J, Bar-Or A, Masterman D, Bernasconi C, Wei W, Garren H, Chin P,  Belachew S,  Arnold D. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Hauser S, Kappos L, Bar-Or A, Hartung H, Belachew S, Han J, Julian L, Napieralski J, Wolinsky J. Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Fox R, Kappos L, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H, Wolf C, Dahlke F, Wallström E, Sidorenko T. Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Herman A, Musch B, Harp C, Han J, Assman B, Fiore D, Masterman D, Cross A, Bar-Or A. Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Cree B, Selmaj K, Kopicko J, Ziemssen T, De Stefano N, Bar-Or A, Comi G, Arnold D, Steinman L, Hartung H, Montalbán X, Havrdova E, Kappos L, Cohen J. The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Fadda G, Brown A, Aubert-Broche B, Banwell B, Collins L., Arnold D, Bar-Or-A*. A ‘surface-in’ gradient of thalamic damage is an early and disease-specific process in pediatric-onset multiple sclerosis. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Cross AH, Herman A, Musch B, Harp C, Han J, Assman B, Fiore D, Masterman D, Bar-Or-A*. Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design. American Academy of Neurology (AAN) 2017 Annual Meeting. Boston, MA. April 2017

Touil H, Li R, Moore C, Antel JP, Bar-Or-A*. Cross-talk between human glial cells and B cells help propagation of CNS-compartmentalized in progressive MS. American Association of Immunology (AAI) 2017 Annual Meeting. Washington, DC. May 2017

Mexhitaj I, Nyirenda M, Arnold D, Marie R.A, Banwell B, Bar-Or-A*. T-cell antigens in pediatric-onset multiple sclerosis: A unique window into early disease mechanisms. American Association of Immunology (AAI) 2017 Annual Meeting. Washington, DC. May 2017

Ludwig Kappos, Amit Bar-Or, Bruce Cree, Robert Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Sophie Arnould, Tatiana Sidorenko, Christian Wolf, Erik Wallström, Frank Dahlke. The EXPAND Study Results: Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017

Ludwig Kappos, Amit Bar-Or, Jeffrey Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jérôme de Seze, Xavier Montalbán, Krzysztof Selmaj, Heinz Wiendl, Algirdas Kakarieka, Goeril Karlsson, Dieter A Häring, Erik Wallström, Stephen L Hauser. Ofatumumab vs. Teriflunomide in Relapsing Multiple Sclerosis: Adaptive Design of Phase 3 ASCLEPIOS I and ASCLEPIOS II Studies. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017.

Robert Fox, Ludwig Kappos, Amit Bar-Or, Bruce Cree, Gavin Giovannoni,

Ralf Gold, Patrick Vermersch, Harald Pohlmann, Christian Wolf, Frank Dahlke, Erik Wallström, Tatiana Sidorenko. Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Results of the Placebo-controlled, Double-blind, Phase 3 EXPAND Study. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017.

L. Kappos, P. Vermersch, A. Bar-Or, R. Gold, R. Fox, B. Cree, B. Magnusson, N. Rouyrre, A. de Vera, C. Wolf, F. Dahlke, G. Giovannoni. Efficacy of Siponimod on Disability Progression in SPMS Patients With and Without OnStudy Relapses. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlan-ds. June 2017.

Fox R, Arnold D.L, BarOr A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H, Sidorenko T, Wolf C, Tomic D, Dahlke F, Kappos L. Effects of Siponimod on MRI Outcomes in Patients With Secondary Progressive Multiple Sclerosis: Results of the Phase 3 EXPAND Study. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017.

Gold R, Giovannoni G, Cree B, VermerschP, Fox R, Bar-Or A, Magnusson B, Rouyrre N, Tomic N, Wolf C, Dahlke F, Leppert D, Kappos L. Impact of Primary Endpoint Definitions and Patient Baseline Characteristics on Study Outcomes in Progressive Multiple Sclerosis. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017.

Bar-Or A*, Derfuss T, Vermersch P, Gold R, Tomic D, Rouyrre5, Sidorenko T, Hillenbrand R, Kappos L. Longitudinal changes in lymphocyte subsets of siponimodtreated patients with SPMS. European Academy of Neurology (EAN) annual meeting 2017. Amsterdam, Netherlands. June 2017.

Fox R, Arnold D.L, Bar-Or A, Cree B, Giovannoni G, Gold R, Vermersch P, Pohlmann H, Sidorenko T, Wolf C, Tomic D, Dahlke F, Kappos L. Effects of Siponimod on MRI Outcomes in Patients With Secondary Progressive Multiple Sclerosis: Results of the Phase 3 EXPAND Study. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting. Paris, France. October 2017.

Fadda G, Brown, R.A., Magliozzi R, Aubert-Broche B, O’Mahony J, Banwell B, Collins D.L., Arnold D.L., Bar-Or A*. Serial MRI detects presence and evolution of a ‘surface-in’ gradient of thalamic damage in paediatric-onset MS, which is recapitulated in adult MS autopsy. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Zipp F, Bar-Or A. New insight into immune related CNS injury. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Ramaglia V, Michailidou M, Touil H, Lee D.S., Ward L.A., van Eden C, Huitinga I, Gommerman J.L., Bar-Or A*. Meningeal inflammation is linked to subpial cortical demyelination in progressive multiple sclerosis with ongoing white matter pathology. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Bar-Or A. Exploring the underlying mechanism of disease. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Comi G, Kappos L, Selmaj K.W., Bar-Or A, Arnold D.L., Steinman L, Hartung H.P., Montalbán X, Havrdová E.K., Cree B.A.C., Sheffield J.K., Raghupathi K, Cohen J.A. Ozanimod demonstrates efficacy and safety in a Phase 3 trial of relapsing multiple sclerosis (SUNBEAM). 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Chitnis T, Arnold D.L., Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostasy K, Tardieu M, Waubant E, Wolinsky J, Bar-Or A, Stites T, Chen Y, Merschhemke M, Gärtner J. PARADIGMS: a randomized double-blind study of fingolimod verses interferon β-1 a in paediatric multiple sclerosis. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Cohen J.A., Comi G, Selmaj K.W., Bar-Or A, Arnold D.L, Steinman L, Hartung H.P., Montalbán X, Havrdová E.K., Cree B.A.C., Sheffield J.K., Raghupathi K, Kappos L. Ozanimod vs interferon β-1 a: clinical and MRI results of RADIANCE part B – A 2-year Phase 3 trial in relapsing multiple sclerosis. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Khadadah S, Kimoff R.J., Duquette P, Jobin V, Lapierre Y, Benedetti A, Robinson A, Roger E, Bar-Or A, Kaminska M, Trojan D.A. Prevalence of sleep apnea in multiple sclerosis patients meeting clinical eligibility criteria for the Sleep Apnea in Multiple Sclerosis Positive Airway Pressure (SAMSPAP) trial. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Lin Y.H., Healy L.M., Jang J.H., Rao V.T.S., Bar-Or A, Antel J.P. Metabolic Control of Macrophage-Mediated Myelin Phagocytosis: Implications for Multiple Sclerosis. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Ghadiri M, Rezk A, Li R, Giacomini P.S., Antel J, Bar-Or A*. Fingolimod-induced changes in the peripheral immune repertoire and their potential as biomarkers of treatment response in multiple sclerosis. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Comi G, Kappos L, Hartung H.P., Arnold D.L., Bar-Or A, Selmaj K.W., Steinman L, Havrdová E.K., Cree B.A.C., Montalbán X, Skolnick B.E., Agafonova N., Cohen J.A. Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in RMS. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Kappos L, Vermersch P, Bar-Or A, Gold R, Fox R, Cree B, Magnusson B, Rouyrre N, de Vera A, Wolf C, Dahlke F, Giovannoni G. Efficacy of Siponimod on Disability Progression in SPMS Patients With and Without On-Study Relapses. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Brown R, Fratila R, Fetco D, Jiang S, Fadda G, Alkhawajah N.M., Banwell B, Bar-Or A, Arnold D.L. Deep Learning to Normalize Conventional T1w MRI for Quantitative Longitudinal Assessment of Tissue Health in MS. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Freedman M.S., Bar-Or A, Benamor M, Truffient P, Poole E, Mandel M, Kremenchutzky M. Long-term Disability Outcomes in Patients Treated with Teriflunomide for up to 14 Years: Group- and Patient-Level Data from the Phase 2 Extension Study. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Bar-Or A*, Derfuss T, Vermersch P, Gold R, Tomic D, Cheviet S, Rourrye N, Sidorenko T, Hillenbrand R, Kappos L. Longitudinal changes in lymphocyte subsets of siponimod-treated patients with SPMS. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Gold R, Giovannoni G, Cree B, Vermersch P, Fox R, Bar-Or A, Magnusson B, Rouyrre N, Tomic D, Wolf C, Dahlke F, Leppert D, Kappos L. Impact of Primary Endpoint Definitions and Patient Baseline chracteristics on Study Outcomes in Progressive Multiple Sclerosis. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Fadda G, Nyirenda M, Mexhitaj I, Healy L, Poliquin-Lasnier L, Hanwell H, Saveriano A, Rozenberg A, Li R, Moore C.S., Belabani C, Johnson T, O’Mahony J, Marrie R.A., Dunn S, Banwell B, Bar-Or A*.  Elevated adiponectin levels induce pro-inflammatory myeloid- and T-cell responses linking adiposity and predisposition to pediatric MS. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Arnold D.L., Cohen J.A., Comi G, Selmaj K.W., Bar-Or A, Steinman L, Hartung H.-P., Montalbán X, Havrdová E.K., Cree B.A.C., Sheffield J.K., Ding N, Kappos L. Ozanimod demonstrates preservation of brain volume at 1 and 2 years in two Phase 3 trials of relapsing multiple sclerosis (SUNBEAM and RADIANCE). 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Suthiophosuwan S, Cheema I, Casserly C, Sankar S, Leung G, Bharatha A, Bar-Or A, Oh J. Intracranial Volume as a Surrogate for Maximal Lifetime Brain Growth in Adult-Onset Multiple Sclerosis: Comparison with Healthy Controls. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Cross A.H., Herman A, Fiore D, Harp C, Musch B, Bar-Or A*. CSF cell signature and biomarkers of neuroinflammation and neurodegeneration in MS: preliminary results of the OBOE study. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Eschborn M, Klotz L, Lindner M, Liebmann M, Torres Garrido B, Breuer J, Schwab N, Gross C, Schulte-Mecklenbeck A, Hundehege P, Nebel G, Glander S, Busch K, Stoll M, Eveslage M, Meuth S.G., Zehn D, Turner T, Bar-Or A, Wiendl H. Inhibition of mitochondrial respiration with teriflunomide modulates antigen-specific immune responses in an affinity-dependent fashion. 7th Joint ECTRIMS – ACTRIMS meeting. Paris, France. October 2017.

Arnold D, Cohen J, Corni G, Selmaj K, Bar-Or A, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Cree B, Sheffield J, Ding N, Kappos L. Ozanimod Demonstrates Preservation of Brain Volume at 1 and 2 Years in Two Phase 3 Trials of Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE). European Charcot Foundation 25th Annual Meeting. Baveno, Italy. Nov 2017.

Selmaj K, Kappos L, Hartung H.-P, Arnold D, Bar-Or A, Comi G, Steinman L,  Havrdová E, Cree B, Montalbán X, Skolnick B, Agafonova N, Cohen J. Cardiac Safety of Ozanimod in a QT/QTc Trial and a Phase 2 Trial in RMS. European Charcot Foundation 25th Annual Meeting. Baveno, Italy. Nov 2017.

Cohen J, Comi G, Selmaj K, Bar-Or A, Arnold D, Steinman L, Hartung H.-P, Montalbán X, Havrdová E, Cree B, Sheffield J, Raghupathi K, Kappos L. Ozanimod vs Interferon -1a: Clinical and MRI Results of RADIANCE Part B – A 2-Year Phase 3 Trial in Relapsing Multiple Sclerosis. European Charcot Foundation 25th Annual Meeting. Baveno, Italy. Nov 2017.

Hartung H.-P, Kappos L, Selmaj K, Bar-Or A, Arnold D, Steinman L, Comi G, Montalbán X, Havrdová E, Cree B, Sheffield J, Raghupathi K, Cohen J. Ozanimod Demonstrates Efficacy and Safety in a Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM). European Charcot Foundation 25th Annual Meeting. Baveno, Italy. Nov 2017.

2016

Wolinsky J, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Hemmer B, Rammohan K, Sauter A, Masterman D, Fontoura P, Garren H, Chin P, Montalbán X, on behalf of the ORATORIO clinical investigators.  Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial.  ACTRIMS, Los Angeles.  February 2016

Cohen JA, Selmaj K, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Olson A, Cravets M, Frohna PA.  Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis.  ACTRIMS, Los Angeles.  February 2016

Montalbán X, Hemmer B, Rammohan K, Giovannoni G, de Seze J, Bar-Or A, Arnold DL, Sauter A, Masterman D, Fontoura P, Chin P, Garren H, Wolinsky J, on behalf of the ORATORIO clinical investigators.  A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS.  ACTRIMS, Los Angeles.  February 2016

Hauser SL, Comi G, Hartung HP, Selmaj K, Traboulsee A, Bar-Or A, Arnold DL, Lublin F, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Kappos L, on behalf of the OPERA I and II clinical investigators.  Efficacy and Safety of Ocrelizumab in Relapsing Multiple Sclerosis: Results of the IFN β-1a-Controlled, Double-Blind, Phase III OPERA I and II Studies.  ACTRIMS, Los Angeles.  February 2016

Moore CS, Galloway DA, Snelgrove A, Durafourt BA, Murphy-Peddle K, Bar-Or A, Antel JP and Stefanelli M. The emergence of microRNAs as biomarkers and disease-relevant targets in MS.  ACTRIMS, Los Angeles.  February 2016

Phillips JT, Bar-Or A, Gold R, Giovannoni G, Fox R, Potts J, Soman T, Marantz J.  Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.  AAN Annual Meeting, Vancouver, BC.  April 2016

Selmaj K, Cohen J, Arnold D, Comi G, Bar-Or A, Gujrathi S, Hartung J, Olson A, Cravets M, Frohna P.  Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis.  AAN Annual Meeting, Vancouver, BC.  April 2016

Kremenchutzky M, Freedman MS, Bar-Or A, Purvis A, Benamor M, Truffinet P, O’Connor PW.  Final Outcomes of the Teriflunomide Phase 2 Extension Study: 13 Years of Efficacy and Safety Results.  AAN Annual Meeting, Vancouver, BC.  April 2016

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Bhasin P, Arnould S, Sidorenko T, Wallstroem E.  Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis.  AAN Ann. Mtg., Vancouver, BC.  April 2016

Healy L, Perron G, Won S-Y, Moore C, Bar-Or A, Antel J.  MerTK as a Functional Regulator of Anti-Inflammatory Myelin Phagocytosis by Human Myeloid Cells. AAN Ann Mtg, Vancouver, BC. April 2016

Wiendl H, Gross CC, Lindner M, Eschborn M, Weisser L, Posevitz-Fejfar A, Schulte-Mecklenbeck A, Van Wijmeersch B, Hupperts R, Brette S, Turner TJ, Bar-Or A, Klotz L.  TERI-DYNAMIC: Exploring the Impact of Teriflunomide on Immune Cell Population Size, Receptor Repertoire, and Function in Patients with RRMS.  AAN Annual Meeting, Vancouver, BC.  April 2016

Warnke C, Mausberg A, Dehmel T, Ingenhoven K, Stettner M, Fitz-Gerald L, Bar-Or A, Antel J, Comabella Lopez M, Montalbán X, Hartung H, Kieseier B.  Preferential Entrapment of Naive T Cells Associates with a Less Diverse T Cell Receptor Repertoire in MS Patients Treated with Fingolimod.  AAN Annual Meeting, Vancouver, BC.  April 2016

Traboulsee AL, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Kappos L, Lublin F, Selmaj K, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Hauser SL.  Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies.  AAN Annual Meeting, Vancouver, BC.  April 2016

Montalbán X, Hemmer B, Rammohan K, Giovannoni G, De Seze J, Bar-Or A, Arnold DL, Sauter A, Masterman D, Fontoura P, Garren H, Chin P, Wolinsky J.  Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study.  AAN Annual Meeting, Vancouver, BC.  April 2016

Arnold DL, Bar-Or A, Comi G, Hartung H-P, Hauser SL, Kappos L, Lublin F, Selmaj K, Traboulsee AL, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Wolinsky J.  Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies.  AAN Annual Meeting, Vancouver, BC.  April 2016

Hauser SL, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Lublin F, Selmaj K, Traboulsee AL, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Kappos L.  Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies.  AAN Ann Mtg, Vancouver, BC.  April 2016

Comi G, Arnold DL, Bar-Or A, Hartung H-P, Hauser SL, Kappos L, Lublin F, Selmaj K, Traboulsee AL, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Montalbán X.  Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies.  AAN Annual Meeting, Vancouver, BC.  April 2016

Bar-Or A, Arnold DL, Comi G, Hartung HP, Hauser SL, Lublin F, Selmaj K, Traboulsee A, Klingelschmitt G, Marcillat C, Napieralski J, Kappos L, on behalf of the OPERA I and OPERA II investigators.  Effect of Ocrelizumab on Humoral Immunity Markers in the Phase III, Double-Blind, Double-Dummy, Interferon β-1a–controlled OPERA I and OPERA II Studies. CMSC Annual Mtg.  National Harbor, MD.  June 2016

Montalbán X, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Hemmer B, Rammohan K, Mairon N, Napieralski J, Sauter A, Wolinsky J, on behalf of the ORATORIO investigators.  Infusion-Related Reactions in the Phase III Double-Blind, Placebo-Controlled ORATORIO Study of Ocrelizumab in Primary Progressive Multiple Sclerosis CMSC Annual Mtg.  National Harbor, MD.  June 2016.  CMSC Annual Mtg.  National Harbor, MD.  June 2016

Selmaj K, Arnold DL, Bar-Or A, Comi G, Hartung HP, Hauser SL, Lublin F, Traboulsee A, Mairon N, Klingelschmitt G, Napieralski J, Kappos L, on behalf of the OPERA I and OPERA II investigators.  Infusion-related Reactions with Ocrelizumab in the Phase III Double-Blind, Double-Dummy, Interferon β-1a–Controlled OPERA I and OPERA II Studies. CMSC Annual Mtg.  National Harbor, MD.  June 2016

Lublin F, Arnold DL, Bar-Or A, Comi G, Hartung HP, Hauser SL, Selmaj K, Traboulsee A, Garas M, Klingelschmitt G, Kappos L, on behalf of the OPERA I and OPERA II investigators. Effect of Ocrelizumab on Clinical Disability in Two Identical Phase III, Double-Blind, Double-Dummy, Interferon β-1a–Controlled Studies. CMSC Annual Mtg.  National Harbor, MD.  June 2016

Wolinsky J, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Hemmer B, Rammohan K, Chin P, Fontoura P, Garren H, Masterman D, Sauter A, Montalbán X, on behalf of the ORATORIO clinical investigators. Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III Placebo-Controlled Trial.  CMSC Annual Mtg. National Harbor, MD.  June 2016

Juzwik C, Zhang Y, Lécuyer M-A, de Faria Junior O, Prat A, Bar-Or A, Fournier A. Immune cell influences on neuronal viability and repair in EAE. CHUM Ann. Neuroinflammation Symp.  Montreal, QC. June 2016

Li R, Rezk A, Gommerman J, Prat A, Bar-Or A, on behalf of the 'Canadian B cells in MS Team'.  IL-10 producing B cells as preferential targets of Atacicept (TACI-Fc): a potential explanation for disease exacerbation in MS.  FOCIS 2016.  Boston, MA.  June 2016

Li, Ghadiri M, Rezk A, Luessi F, Zipp F, Giacomini P, Antel J, Bar-Or A. Dimethyl fumarate (DMF) treatment mediates an anti-inflammatory shift in B cell subsets of patients with Multiple Sclerosis FOCIS 2016.  Boston, MA.  June 2016

Rezk A, Li R, Luessi F, Prat A, Gommerman J, Zipp F, Bar-Or A.  An optimized approach for isolating viable human cytokine-defined B cells. FOCIS 2016.  Boston, MA. , June 2016

Rezk A, Li R, Luessi F, Prat A, Gommerman J, Zipp F, Bar-Or A.  Interactions of B cell and CD8 T cell subsets and their implication in multiple sclerosis.  FOCIS 2016.  Boston, MA.  June 2016

Aktas O, Hauser SL, Arnold DL, Bar-Or A, Comi G, Hartung HP, Lublin F, Selmaj K, Traboulsee A, Chin P, Fontoura P, Garren H, Klingelschmitt G, Masterman D, Kappos L, on behalf of the OPERA I and II clinical investigators.  Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Results of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies.  Annual DGN Congress (German Society of Neurology).  Mannheim, Germany. September 2016

Goebels N, Montalbán X, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Rammohan K, Chin P, Fontoura P, Garren H, Masterman D, Sauter A, Wolinsky J, on behalf of the ORATORIO clinical investigators.  Efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis: Results of the phase III, double-blind, placebo-controlled ORATORIO study. Annual DGN Congress (German Society of Neurology).  Mannheim, Germany. September 2016

Goebels N, Wolinsky J, Arnold DL, Bar-Or A, de Seze J, Giovannoni G, Rammohan K, Sauter A, Masterman D, Fontoura P, Garren H, Chin P, Montalbán X, on behalf of the ORATORIO clinical investigators.  Efficacy of ocrelizumab in patients with PPMS with and without T1 gadolinium-enhancing lesions at baseline in a phase III, placebo-controlled trial. Annual DGN Congress (German Society of Neurology).  Mannheim, Germany. September 2016

Kappos L, Traboulsee A, Arnold DL, Bar-Or A, Hartung HP, Lublin F, Selmaj K, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Hauser SL, on behalf of the OPERA I and OPERA II clinical investigators.  Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients With Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon Beta-1a–Controlled.  Swiss Federation of Clinical Neuro-Societies (SFCNS) Congress.  Basel, Switzerland.  Sept 2016

Derfuss T, Hauser SL, Arnold DL, Bar-Or A, Hartung HP, Lublin F, Selmaj K, Traboulsee AL, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Kappos L, on behalf of the OPERA I and OPERA II investigators.  Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: Pooled analysis of two Identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Swiss Federation of Clinical Neuro-Societies (SFCNS) Congress.  Basel, Switzerland.  Sept 2016

Gobbi C, Arnold DL, Bar-Or A, Hartung HP, Hauser SL, Lublin F, Selmaj K, Traboulsee AL, Klingelschmitt G, Masterman D, Fontoura P, Chin P, Garren H, Wolinsky J, Kappos L, on behalf of the OPERA I and OPERA II investigators.  Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-blind, Double-dummy, interferon beta-1a- controlled OPERA I and OPERA II Studies.  Swiss Federation of Clinical Neuro-Societies (SFCNS) Congress.  Basel, Switzerland.  Sept 2016

Selmaj K, Cohen JA, Arnold DL, Comi G, Bar-Or A, Olson A, Kopicko J, Frohna PA.  Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis.  European Charcot Foundation Symposium.  November 2016

Books

Chapters

2011

Chitnis T, Bar-Or A. Pediatric MS: Biological presentation and research update. In: Demyelinating Disorders of the Central Nervous System in Childhood. Chabas D and Waubant EL, Eds. Cambridge Univ. Press, 2011

Waubant E and Bar-Or A. B cell based therapies for MS. In: Multiple Sclerosis Therapeutics. Cohen J and Rudick R, Eds. Cambridge University Press, 4 edition, 30 Nov 2011

Darlington P and Bar-Or A*. Immunology of MS. In: Multiple Sclerosis Therapeutics. Cohen J and Rudick R, Eds. Cambridge University Press; 4th Edition, Nov 30 2011

2008

Dubeau F, Andermann F, Wiendl H and Bar-Or A, Rasmussen’s encephalitis (chronic focal encephalitis). In: Epilepsy: A Comprehensive Textbook, Engel P and Pedley T, Eds. Lippincott Williams & Wilkins. 2nd edition. Vol 3: 2439-2454;2008

2006

Bar-Or A. Looking Ahead: The Future of Multiple Sclerosis. Advanced Studies in Medicine. Multiple Sclerosis update: John’s Hopkins Press, 2006

Bar-Or A. Human Immune studies in Multiple Sclerosis and Demyelinating Diseases. In: Advances in Neurology; Freedman M, Ed. Lippincott Williams & Wilkins, 98:91-109, 2006

2005

Bar-Or A. Immunology of Multiple Sclerosis. In: Multiple Sclerosis. Wolinsky J, Ed.  Elsevier Press, Neurologic Clinics, 23(1):149-175, 2005

2004

Antel JP and Bar-Or A. Multiple Sclerosis: Therapy. In: Myelin Biology and Disorders.  Lazzarini RA, Ed. Elsevier Press, pp. 791-806, 2004

2003

Antel JP and Bar-Or A. Multiple Sclerosis. In: Conn’s Current Therapy. 55th edition. Rakel RE and Bope ET, editors. W.B. Saunders Company. pp 997-1006, 2003

2002

Anderson DE, Bar-Or A, Hafler DA. Molecular pathology of multiple sclerosis. In: The Molecular Pathology of Autoimmune Diseases. 2nd Edition. Argyrios N. Theofilopoulos, Ed. Taylor and Francis Publishers, New York, NY. 2002

2001

Bar-Or A, O’Connor K and Hafler DA. Multiple Sclerosis. In:  Samter’s Immunologic Diseases. 6th Ed. Austen, Frank, Atkinson and Cantor, Eds. Lippincott Williams and Wilkins. pp 711-737, 2001

Bar-Or A and Smith D. Epidemiology of Multiple Sclerosis. In: Textbook of Neuroepidemiology. Batchelor T, Cudcowicz M, editors. Butterworth Heinemann. 2001

Posters and Presentations

Invited Lectures

2018

Bar-Or A. Emerging Themes in the Neuroimmunology of Multiple Sclerosis. Neuroscience Symposium. Uniformed Services University Hospital. Bethesda MD, Jan 2018

Bar-Or A. B cells: Bedside to Bench and Back. Joint Neurology, Neurosurgery and Neroscience Rounds. Temple University. Philadelphia, Jan 2018

Bar-Or A. Immune Monitoring Platforms: Functional Cell-based Assays. GJGFF and Immune Tolerance Network. Palos Verdes, CA, Feb 2018.

Bar-Or A. HSCT in MS: Reshaping the immune system and long term impact on disease activity. ACTRIMS 2018 Forum. San Diego, CA. February 2018.

Bar-Or A. Emerging Themes in Neuroimmunology of MS. Neurology Grand Rounds. Icahn School of Medicine at Mount Sinai. New York City, NY, Mar 2018.

Bar-Or A. Emerging Themes in Neuroimmunology of MS. Neuroscience Rounds. Beth Israel Hospital. New York City, NY, Mar 2018.

Bar-Or A. Translational Neuroimmunology in Multiple Sclerosis. Thomas Jefferson University Grand Rounds. Philadelphia, PA, May 2018.

Bar-Or A. Interim Analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Study in Multiple Sclerosis (MS). AAN. Los Angeles, CA, April 2018. 

Bar-Or A. VELOCE Vaccine Study – Results for Ocrelizumab in MS. AAN. Los Angeles, CA, April 2018

Bar-Or A. Evolving Themes in MS immune-pathophysiology and case discussion. Barzilay Medical Center, Ashkelon, Israel, May 2018

Bar-Or A. Neuroimmunology of MS. Hadassah University Medical Center Grand Rounds. Jerusulem, Israel. May 2018.

Bar-Or A. Emerging Roles of B cells in MS. Technion, Haifa, Israel, May 2018.

Bar-Or A. Treatment Considerations in MS. RAMBAM Hospital. Haifa, Israel. May 2018.

Bar-Or A. Emerging Themes in MS Neuroimmunology. Jefferson Grand Rounds, Philadelphia, May 2018

Bar-Or A. Precision Medicine in Neuroimmunology. Keynote Address, Inaugural CNS Precision Medicine Symposium, Wayne State University, Dteroit, MI, May 2018.

Bar-Or A. Basic Neuroimmunoloy for Neurologists. Immunotherapy for Neurologic Disorders 2018 CME. Philadelphia, June 2018.

Bar-Or A. Immune Neural Interactions and CNS-compartmentalized Inflammation in MS. FOCIS 2018, San Francisco, June 2018.

Bar-Or A. What Children Can Teach Us About MS. ISNI 2018, Brisbane Australia, Aug 2018.

2017

Bar-Or A. Emerging concepts in MS pathogenesis.  Weill Cornell Neuorology Grand Rounds.  New York, NY.        Jan 2017

Bar-Or A. Multiple Sclerosis: Emerging Insights Across The Age-Span. Joint Grand Rounds, Department of Neurology, University of Pennsylvania, PA, Jan 2017

Bar-Or A. Emerging Themes in Multiple Sclerosis Neuroimmunology. Philadelphia Neurological Society. Philadelphia, PA. Feb 2017.

Bar-Or A. B Cell Cytokine Networks in Autoimmune Disease.  Center for Childhood Cancer Seminar Series.  CHOP; Philadelphia, PA.  Feb 2017.

Bar-Or A. The compartmentalized immune response in MS.  Annual Excemed conference in multiple sclerosis. Rome, Italy. Mar 2017 

Bar-Or A. Neuroinflammation in Multiple Sclerosis. Biomarker challenges and opportunities. Biomarkers in Neuroinflammation Workshop. National Academy of Sciences, Washington DC, Mar 2017

Bar-Or A. Targeting Antibody-Independent B Cell Functions in Multiple Sclerosis. TrialNET annual meeting, Denver, CO, Mar 2017.

Bar-Or A. Emerging Themes in Neuroimmunology of MS. Neuroinflammatory Symposium. Children's Hospital of Pennsylvania, University of Pennsylvania, Philadelphia, PA, Apr 2017

Bar-Or A. Targeting B cell cytokine networks in T cell-mediated autoimmune disease. American Association of Immunology Major Symposium. AAI Annual Meeting. Washington, DC. May 2017

Bar-Or A. RRMS and SPMS Transition: Where are the limits? Annual Spanish Neurology Meeting. Madrid, Spain. Jun 2017

Bar-Or A. Progressive MS: Clinical and research perspectives. Annual Spanish Neurology Meeting. Madrid, Spain. Jun 2017

Bar-Or A. Charcot Lecture: Emerging Themes in Neuroimmunology of MS. Charcot Lecture, NIH. Bethesda, MD. Jun 2017

Bar-Or A. The few teaching us about the many: Lessons from special populations in MS. Neurology Grand Rounds, NIH. Bethesda, MD. Jun 2017

Bar-Or A. Is MS not a T-cell mediated disease? Keystone Symposium in Neuroinflammation. Keystone, CO. Jun 2017

Bar-Or A. MS neuroimmunology and B-eyond. Annual Argentenian Association of Neurology meeting. Buenos Aires, Argentina. Aug 2017

Bar-Or A. Emerging Themes in MS Pathogenesis. Annual Japanese Neuroimmunology Society Meeting. Sapporo and Tokyo, Japan. Oct. 2017

Bar-Or A. Mechanisms and Therapeutic Targets in Multiple Sclerosis. Autoimmunity Meeting. University of Toronto, ON. Oct 2017

Bar-Or A. Tanenbaum Keynote Speaker. Emerging Mechanisms in CNS Inflammatory Disease. University of Toronto, ON. Oct 2017

Bar-Or A. Interactions between B cells, T cells and Myeloid in MS, annual American Neurological Association (ANA) meeting, San Diego Oct 2017

Bar-Or A. B cell:T cell:Myeloid checkpoints. Annual ECTRIMS meeting, London, UK, Oct 2017

Bar-Or A. Emerging Themes in MS: B cells, T cells and Introduction to B Cell Therapies. Yale University, Nov 2017

Bar-Or A. B cell subsets and their roles in MS. At The Limits in Multiple Sclerosis.  The Royal College of Physicians, London, UK, Nov 2017

Bar-Or A. The role of B cells in MS: From Hypothesis to Clinical Practice. The annual Israeli Neurological Association Meeting, Rosh Pina, Israel, Dec 2017

Bar-Or A. B cell Targeting in MS with ocrelizumab. Neurology Rounds, Sheba Medical Center, Tel Hashomer, Israel, Dec 2017.

Bar-Or A. Immune Mechanisms in Neuro Inflammatory Diseases. Fatigue Workshop: Challenges and Opportunities. UPenn, Dec 2017

2016

Bar-Or A. B Cells in MS: Roles Redefined, The Göttingen Lecture. Göttingen, Germany.  February 2016

Bar-Or A. MS immune pathogenesis, ACTRIMS.  New Orleans, LA.  February 2016

Bar-Or A. Emerging immune modulators in MS, ACTRIMS.  New Orleans, LA.  February 2016

Bar-Or A. Current recommendations on vitamin D for people living with MS, MSSC Expert Panel Mtg.  Toronto, ON.  March 2016

Bar-Or A. Revisiting the roles of T cells and B cells in MS. EXCEMED Ann Conf. in MS. Berlin, Germany. Apr 2016

Bar-Or A. Targeting functionally distinct B Cell subsets in autoimmune disease.  Canadian Society of Immunology Symposium. Ottawa, ON. Apr 2016

Bar-Or A. B cells in multiple sclerosis, CRNI.  Bergamo, Italy.  April 2016

Bar-Or A. B cell biology in multiple sclerosis, Int’l Congress on Autoimmunity.  Leipzig, Germany.  Apr 2016

Bar-Or A. Immune mechanisms in multiple sclerosis.  Verily MS Innovation Workshop.  Cambridge, MA. May 2016

Bar-Or A. Targeting B cells and T cells in MS; current and future treatment perspectives.  CMSC Annual Mtg. National Harbour, MD. June 2016

Bar-Or A. GM-CSF expressing B cells in autoimmune disease.  CSI-AAI Symposium.  Seattle, WA.  May 2016

Bar-Or A. Update on neuroimmunology of MS.  Japan Tour – Sapporo/Tokyo/Sendai.  July 2016

Bar-Or A. B cell contribution to peripheral inflammation.  ISNI 14th Int’l Congress.  Jerusalem, Israel.  Sep 2016

Bar-Or A. B cells in pathogenesis of MS.  ISNI 14th Int’l Congress.  Jerusalem, Israel.  Sep 2016

Bar-Or A. Evolving concepts in MS Biology and Therapeutics.  T. Evans Wyckoff Lecture in Neuroscience at Virginia Mason Medical Center. Seattle, WA. Oct 2016

Bar-Or A. B cell roles Redefined.  Benaroya Research Institute, Seattle, WA. Oct 2016

Bar-Or A. The role of B cells in CNS demyelinating disease.  9th PACTRIMS Congress. Bangkok, Thailand. Oct 2016

Bar-Or A. Immune suppression vs immune modulation: An immunologist’s perspective.  9th PACTRIMS Congress. Bangkok, Thailand. Oct 2016

Bar-Or A. From genes to cure. Inaugural MRCCT Symposium, Montreal, Nov 2016. 

Bar-Or A. Interplay between inflammation and neurodegeneration in progressive MS. MSSC endMS Conference. Toronto, ON.  Dec 2016